Messenger RNA (mRNA) therapeutics have moved from a promising idea to clinical reality, accelerating vaccine development and opening new paths ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture. As the numbers of poorly soluble and complex molecules, such ...

According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for the ...

For the pharmaceutical industry, drug formulation is a cornerstone, crucial for converting bioactive molecules into effective, stable, and patient-friendly medications. For the pharmaceutical industry ...

The success of the mRNA vaccines for COVID-19 led to explosive growth in lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As these projects scale into clinical trials ...

Lipid nanoparticle formulation has increased over the past two decades. LNPs have proven to be effective nano-based delivery vehicles for cytotoxic chemotherapeutic drugs, nucleic acid therapies and ...

The precision medicine market is projected to exceed $175 billion by 2030, reflecting continued growth and interest in innovative approaches that tailor therapeutics that accounts for differences in ...